Fundamental analysis · SEC EDGAR · TTM through 31/03/2026
WST · NYSE · Healthcare
Fundamental quality
65
out of 100
Source: SEC EDGAR · TTM through 31/03/2026
The score combines growth, profitability and financial strength. Here its financial strength weighs in its favor, while its growth drags it down the most.
| Year | Revenue | Net income | Free cash flow | Net debt |
|---|---|---|---|---|
| 2021 | $2,832M | $662M | $331M | -$510M |
| 2022 | $2,887M | $586M | $439M | -$685M |
| 2023 | $2,950M | $593M | $415M | -$647M |
| 2024 | $2,893M | $493M | $276M | -$282M |
| 2025 | $3,074M | $494M | $469M | -$588M |
Between 2021 and 2025, revenue went from $2,832M to $3,074M (+9%) and net income went from $662M to $494M (-25%).
Annual figures in U.S. dollars per SEC filings. Net debt is total debt minus cash.
Is West Pharmaceutical Services Inc a profitable company?
Yes. West Pharmaceutical Services Inc shows a net margin of 16.8% and an ROE of 18.1%, a sign of a profitable business.
Does West Pharmaceutical Services Inc have a lot of debt?
No. West Pharmaceutical Services Inc has a net cash position: more cash than debt.
Is West Pharmaceutical Services Inc growing?
Its revenue has grown 3.4% annualized in recent years.
Does West Pharmaceutical Services Inc generate cash?
Yes. It converts about 14.2% of its revenue into free cash flow.
The thresholds are general and the system doesn't judge qualitative factors. See the full methodology and use this analysis as a first filter, never as a final decision.
Is West Pharmaceutical Services Inc cheap or expensive?
That depends on the current price. Look it up, enter it in the tool and get the full valuation verdict (P/E against its sector).
Compute the valuation →Brokers you can use to invest in U.S. and European stocks.
The serious investor's standard →
Popular in the U.S. →
Other analyses
NVIDIA (NVDA) · Microsoft (MSFT) · Apple (AAPL) · Alphabet (Google) (GOOGL) · Amazon (AMZN) · Meta Platforms (META) · see more →